Inhibition of the development of experimental diabetic neuropathy by suppression of AGE formation with a new antiglycation agent

International Congress Series

Volumn 1245, Issue C, 2002, Pages 101-105

  Wada, Ryuichi ^a   Nishizawa, Yusuke ^a   Yagihashi, Norito ^a   Takeuchi, Masayoshi ^b   Ishikawa, Yutaro ^c   Yasumura, Kou ^c   Nakano, Masahiko ^d   Yagihashi, Soroku ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^d MITSUBISHI GAS CHEMICAL COMPANY INC   (Japan)

Author keywords

Advanced glycation endproducts; Diabetic neuropathy; OPB 9195; Oxidative stress

Indexed keywords

EID: 84896282519     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0531-5131(02)00998-6     Document Type: Article

References (22)

1. Yagihashi, S., Pathology and pathogenetic mechanisms of diabetic neuropathy. Diabetes Metab. Rev. 11:3 (1995), 193–225.
2. Vlassara, H., Brownlee, M., Cerami, A., Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus. Proc. Natl. Acad. Sci. U. S. A. 78:8 (1981), 5190–5192.
3. Sugimoto, K., Nishizawa, Y., Horiuchi, S., Yagihashi, S., Localization in human diabetic peripheral nerve of Nε-carboxymethyllysine-protein adducts, an advanced glycation endproduct. Diabetologia 40:12 (1997), 1380–1387.
4. Nakamura, S., Makita, Z., Ishikawa, S., Yasumura, K., Fujii, W., Yanagisawa, K., et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46:5 (1997), 895–899.
5. Wada, R., Nishizawa, Y., Yagihashi, N., Takeuchi, M., Ishikawa, Y., Yasumura, K., et al. Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy. Eur. J. Clin. Investig. 31:6 (2001), 513–520.
6. Takeuchi, M., Makita, Z., Yanagisawa, K., Kameda, Y., Koike, T., Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol. Med. 5:6 (1999), 393–405.
7. Ling, X., Sakashita, N., Takeya, M., Nagai, R., Horiuchi, S., Takahashi, K., Immunohistochemical distribution and subcellular localization of three distinct specific molecular structures of advanced glycation end products in human tissues. Lab. Invest. 78:12 (1998), 1591–1606.
8. Toyokuni, S., Tanaka, T., Hattori, Y., Nishiyama, Y., Yoshida, A., Uchida, K., et al. Quantitative immunohistochemical determination of 8-hydroxy-2′-deoxyguanosine by a monoclonal antibody N45.1: its application to ferric nitrilotriacetate-induced renal carcinogenesis model. Lab. Invest. 76:3 (1997), 365–374.
9. Wada, R., Koyama, M., Mizukami, H., Odaka, H., Ikeda, H., Yagihashi, S., Effects of long-term treatment with alpha-glucosidase inhibitor on the peripheral nerve function and structure in Goto–Kakizaki rats: a genetic model for type 2 diabetes. Diabetes Metab. Res. Rev. 15:5 (1999), 332–337.
10. +)-ATPase activity and thrombomodulin expression in streptozotocin-induced diabetic rats. Diabetologia 42:6 (1999), 743–747.
11. Takeuchi, M., Bucala, R., Suzuki, T., Ohkubo, T., Yamazaki, M., Koike, T., et al. Neurotoxicity of advanced glycation endproducts for cultured cortical neurons. J. Neuropathol. Exp. Neurol. 59:12 (2000), 1094–1105.
12. Chakravarthy, U., Hayes, R.G., Stitt, A.W., McAuley, E., Archer, D.B., Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes 47:6 (1998), 945–952.
13. Bucala, R., Tracey, K.J., Cerami, A., Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J. Clin. Invest. 87:2 (1991), 432–438.
14. Schmidt, A.M., Hori, O., Chen, J.X., Li, J.F., Crandall, J., Zhang, J., et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest. 96:3 (1995), 1395–1403.
15. Vlassara, H., Fuh, H., Donnelly, T., Cybulsky, M., Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol. Med. 1:4 (1995), 447–456.
16. Wautier, J.L., Wautier, M.P., Schmidt, A.M., Anderson, G.M., Hori, O., Zoukourian, C., et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc. Natl. Acad. Sci. U. S. A. 91:16 (1994), 7742–7746.
17. Miyata, T., Ishikawa, S., Asahi, K., Inagi, R., Suzuki, D., Horie, K., et al. 2-Isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide (OPB-9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery: role of glycoxidation and lipoxidation reactions in vascular tissue damage. FEBS Lett. 445:1 (1999), 202–206.
18. + ATPase impairment and experimental glycation: the role of glucose autoxidation. Free Radic. Res. 24:5 (1996), 381–389.
19. Kihara, M., Schmelzer, J.D., Poduslo, J.F., Curran, G.L., Nickander, K.K., Low, P.A., Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc. Natl. Acad. Sci. U. S. A. 88:14 (1991), 6107–6111.
20. Vlassara, H., Brownlee, M., Manogue, K.R., Dinarello, C.A., Pasagian, A., Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 240:4858 (1988), 1546–1548.
21. Yamagishi, S., Yonekura, H., Yamamoto, Y., Katsuno, K., Sato, F., Mita, I., et al. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J. Biol. Chem. 272:13 (1997), 8723–8730.
22. Bierhaus, A., Illmer, T., Kasper, M., Luther, T., Quehenberger, P., Tritschler, H., et al. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 96:7 (1997), 2262–2271.